What changed from existing technology?
This study looked at how well atorvastatin lowers bad cholesterol in patients who had a specific type of heart attack, and found that both medical history and genetic factors play a role in how much the cholesterol decreases.
This is the first study to identify specific genetic variants associated with LDL-C response to atorvastatin in patients with ST-elevation myocardial infarction.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
disease, yet response to statin therapy varies between patients. We investigated clinical and genetic factors associated with LDL-C response to atorvastatin i
Abstract ↗. After exclusion of singleton variants, 176 variants remained for analysis, including 68 rare variants (minor allele frequency < 0.05). In single-varian
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This research could help identify patients who may not respond well to atorvastatin, allowing for more personalized cholesterol management after a heart attack.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.